Urological Treatment Details
Medical Management for BPH:

Over the years, researchers have tried to find a way to shrink or at least stop the growth of the prostate without using surgery. The FDA has approved six drugs to relieve common symptoms associated with an enlarged prostate.

Finasteride (Proscar), FDA-approved in 1992, and dutasteride (Avodart), FDA-approved in 2001, inhibit production of the hormone DHT, which is involved with prostate enlargement. The use of either of these drugs can either prevent progression of growth of the prostate or actually shrink the prostate in some men.

The FDA also approved the drugs terazosin (Hytrin) in 1993, doxazosin (Cardura) in 1995, tamsulosin (Flomax) in 1997, and alfuzosin (Uroxatral) in 2003 for the treatment of BPH. All four drugs act by relaxing the smooth muscle of the prostate and bladder neck to improve urine flow and to reduce bladder outlet obstruction. The four drugs belong to the class known as alpha blockers. Terazosin and doxazosin were developed first to treat high blood pressure. Tamsulosin and alfuzosin were developed specifically to treat BPH.

The Medical Therapy of Prostatic Symptoms (MTOPS) Trial, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), recently found that using finasteride and doxazosin together is more effective than using either drug alone to relieve symptoms and prevent BPH progression. The two-drug regimen reduced the risk of BPH progression by 67 percent, compared with 39 percent for doxazosin alone and 34 percent for finasteride alone.

Related conditions: BPH    


  
References:

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES

National Kidney and Urologic Diseases
Information Clearinghouse (NKUDIC)

National Institutes of Health
NIH Publication No. 07-3012
Date: June 2006

Websites for Additional Information:

AUAFoundation - The Official Foundation of the American Urological Association

NKDEP - National Kidney Disease Education Program

NKUDIC-National Kidney and Urologic Diseases
Information Clearinghouse

National Kidney and Urologic Diseases
Information Clearinghouse (NKUDIC)Kidney and Urologic Diseases A-Z list of Topics and Titles

Enid Urology Associates, Inc. 615 E. Oklahoma, Suite 202 ~ Enid, Oklahoma 73703
Phone: 580.233.3230  Fax: 580.233.0698

© Copyright 2012. Enid Urology Associates, Inc. - All rights reserved.